All Stories

  1. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways

    Article • Drug Design Development and Therapy, December 2019, Taylor & Francis

    yunchen Luo

  2. Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

    Article • Diabetes Metabolic Syndrome and Obesity, July 2019, Dove Medical Press

    yunchen Luo, Harvest Gu

  3. Prevalence of abnormal glucose homeostasis in Chinese patients with non-transfusion-dependent thalassemia

    Article • Diabetes Metabolic Syndrome and Obesity, April 2019, Dove Medical Press

    yunchen Luo